CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia

• Egile Nagusiak: Carlos Cuesta-Mateos (Egilea), Patricia Fuentes (Egilea), Alexandra Schrader (Egilea), Raquel Juárez-Sánchez (Egilea), Javier Loscertales (Egilea), Tamara Mateu-Albero (Egilea), Lorena Vega-Piris (Egilea), Marina Espartero-Santos (Egilea), Ana Marcos-Jimenez (Egilea), Blanca Andrea Sánchez-López (Egilea), Yaiza Pérez-García (Egilea), Dennis Jungherz (Egilea), Sebastian Oberbeck (Egilea), Linus Wahnschaffe (Egilea), Anna Kreutzman (Egilea), Emma I. Andersson (Egilea), Satu Mustjoki (Egilea), Edgar Faber (Egilea), Ana Urzainqui (Egilea), Manuel Fresno (Egilea), Kostantino Stamatakis (Egilea), Arantzazu Alfranca (Egilea), Fernando Terrón (Egilea), Marco Herling (Egilea), María Luisa Toribio (Egilea), Cecilia Muñoz-Calleja (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2020-10-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies. Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all patients relapse. Therefore, there is an unmet medical need f...